Based on the Avadel Pharmaceuticals PLC stock forecast from 4 analysts, the average analyst target price for Avadel Pharmaceuticals PLC is USD 24.86 over the next 12 months. Avadel Pharmaceuticals PLC’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Avadel Pharmaceuticals PLC is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Avadel Pharmaceuticals PLC’s stock price was USD 9.94. Avadel Pharmaceuticals PLC’s stock price has changed by -10.85% over the past week, -33.95% over the past month and -20.67% over the last year.
No recent analyst target price found for Avadel Pharmaceuticals PLC
No recent average analyst rating found for Avadel Pharmaceuticals PLC
Company Overview Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, 2 Read Less
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narco...Read More
Frequently Asked Questions About Avadel Pharmaceuticals PLC (AVDL) Stock
Based on ratings from 4 analysts Avadel Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on AVDL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AVDL is USD 24.86 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 22.
AVDL stock's Price/Earning ratio is 60.92.
Our analysis grades AVDL stock's Price / Earning ratio at F. This means that AVDL stock's Price/Earning ratio is above 76% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this AVDL may be a overvalued for its sector.
The last closing price of AVDL's stock was USD 9.94.
The most recent market capitalization for AVDL is USD 1.27B.
Based on targets from 4 analysts, the average taret price for AVDL is projected at USD 24.86 over the next 12 months.
This means that AVDL's stock price may go up by +150.07% over the next 12 months.
We can't find any ETFs which contains Avadel Pharmaceuticals PLC's stock.
As per our most recent records Avadel Pharmaceuticals PLC has 154 Employees.
Avadel Pharmaceuticals PLC's registered address is 10 Earlsfort Terrace, Dublin, Ireland, 2.
You can get more information about it from Avadel Pharmaceuticals PLC's website at https://www.avadel.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Avadel Pharmaceuticals PLC (AVDL) Stock
Based on ratings from 4 analysts Avadel Pharmaceuticals PLC's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and hold ratings.
Unfortunately we do not have enough data on AVDL's stock to indicate if its a good dividend stock.
Based on targets from 4 analysts, the average taret price for AVDL is USD 24.86 over the next 12 months. The maximum analyst target price is USD 29 while the minimum anlayst target price is USD 22.
AVDL stock's Price/Earning ratio is 60.92.
Our analysis grades AVDL stock's Price / Earning ratio at F. This means that AVDL stock's Price/Earning ratio is above 76% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this AVDL may be a overvalued for its sector.
The last closing price of AVDL's stock was USD 9.94.
The most recent market capitalization for AVDL is USD 1.27B.
Based on targets from 4 analysts, the average taret price for AVDL is projected at USD 24.86 over the next 12 months.
This means that AVDL's stock price may go up by +150.07% over the next 12 months.
We can't find any ETFs which contains Avadel Pharmaceuticals PLC's stock.
As per our most recent records Avadel Pharmaceuticals PLC has 154 Employees.
Avadel Pharmaceuticals PLC's registered address is 10 Earlsfort Terrace, Dublin, Ireland, 2.
You can get more information about it from Avadel Pharmaceuticals PLC's website at https://www.avadel.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVDL !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
